Generally, performance measures are developed from Class 1 CORs and Level A and B LOEs (ie, strong recommendations based on the highest quality of evi- dence), but quality measures are generally based on lower ranges of CORs and LOEs. This distinction is important to remember throughout the present docu- ment, given that performance measures are most com- monly designed to be considered for use in national quality payment and reporting programs by entities such as the Centers for Medicare & Medicaid Services (CMS) and the National Committee for Quality Assur- ance (NCQA), whereas quality measures are typically designed to support quality improvement initiatives and activities at the national or microsystem levels. The effective implementation of this measure set by clinicians, care teams, and health systems will lead to significant improvements in effective detection and treatment of HBP for millions of people across the Unit- ed States. Specifications for these new measures take into full account the revised classification taxonomy of HBP from the 2017 Hypertension Clinical Practice as noted in Table 2. The writing committee felt that it was critically impor- tant to incorporate this revised classification into the con- struction of each of the new performance and quality measures presented in this document. The writing com- mittee believed that the former HBP classification scheme previously published by the Joint National Committee5 was now out of date and needed replacement with that of the 2017 Hypertension Clinical Practice Guidelines,4 described in Table 2, to reduce confusion in the field. The current International Classification of Diseases, 10th edi- tion, codes have not yet been modified to reflect the new classification from the 2017 Hypertension Clinical Prac- which may create some initial challenges with implementation. 